Ruben Nzouakou,
Dora Bachir, Anne Lavaud,
Anoosha Habibi,
Ketty Lee,
François Lionnet,
Anne Hulin,
Hélène Jouault,
Claude Préhu,
Françoise Roudot-Thoraval,
Robert Girot,
Frédéric Galactéros
[show abstract]
[hide abstract]
ABSTRACT: Hydroxyurea-derived clinical and biological benefits and safety were retrospectively studied for 123 adult patients from 2 sickle cell disease referral centers during a total follow-up of 654 patient-years and total hydroxyurea exposure of 549 patient-years. Fifty-six adverse events occurred (incidence: 12%/patient-year), with leg ulcers being the most frequent. Adverse events could arise at any time and were usually reversible. No malignancy was observed. Clinical and biological benefits of our cohort were similar to those previously reported. Based on this relatively long retrospective study, the risk/benefit ratio for moderate hydroxyurea doses was satisfactory.
Acta Haematologica 12/2010; 125(3):145-52. · 1.35 Impact Factor
